Cargando…

Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension

PURPOSE: We hypothesized that due to its specific characteristics, the Casper(TM) RX carotid stent (CP) might be particularly suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we compared it to the commonly used Precise Pro RX(...

Descripción completa

Detalles Bibliográficos
Autores principales: Belachew, Nebiyat F., Baschung, Severin, Almiri, William, Encinas, Ruben, Kaesmacher, Johannes, Dobrocky, Tomas, Schankin, Christoph J., Abegg, Mathias, Piechowiak, Eike I., Raabe, Andreas, Gralla, Jan, Mordasini, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463398/
https://www.ncbi.nlm.nih.gov/pubmed/34003319
http://dx.doi.org/10.1007/s00062-021-01024-2
_version_ 1784572396513001472
author Belachew, Nebiyat F.
Baschung, Severin
Almiri, William
Encinas, Ruben
Kaesmacher, Johannes
Dobrocky, Tomas
Schankin, Christoph J.
Abegg, Mathias
Piechowiak, Eike I.
Raabe, Andreas
Gralla, Jan
Mordasini, Pasquale
author_facet Belachew, Nebiyat F.
Baschung, Severin
Almiri, William
Encinas, Ruben
Kaesmacher, Johannes
Dobrocky, Tomas
Schankin, Christoph J.
Abegg, Mathias
Piechowiak, Eike I.
Raabe, Andreas
Gralla, Jan
Mordasini, Pasquale
author_sort Belachew, Nebiyat F.
collection PubMed
description PURPOSE: We hypothesized that due to its specific characteristics, the Casper(TM) RX carotid stent (CP) might be particularly suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we compared it to the commonly used Precise Pro RX(TM) stent (PP). METHODS: A total of 15 patients with IIH (median age 28.7 years) were reviewed retrospectively. Technical aspects as well as peri- and postinterventional complication rates were examined in patients treated with CP (n = 10) and the PP (n = 5). Improvements in cerebrospinal fluid opening pressure (CSF OP), transstenotic pressure gradient (TSPG) and clinical symptoms were also assessed. RESULTS: Stent delivery was easier and more successful with the CP than the PP (difficult/failed stent delivery 0.0% versus 57.1%) and consequently achieved with less attempts (≥ 2: 0.0% versus 40.0%). No severe peri- or postinterventional complications or instances of in-stent thrombosis and/or stenosis were observed during follow-up. Improvement of CSF OP and TSPG immediately after VSS as well as at 6‑month follow-up was comparable between the CP and PP group. Both groups showed substantial and similar decreases in intensity and frequency of headache. Almost all patients with other IIH-related symptoms showed either improvement or complete resolution of those symptoms after VSS. All patients who were available for interview (n = 12/15) reported a substantial improvement in quality of life. CONCLUSION: VSS using the CP seems to be safe and effective. The CP may reduce the risk of difficult or failed stent delivery in patients with challenging intracranial venous anatomy. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01024-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8463398
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84633982021-10-08 Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension Belachew, Nebiyat F. Baschung, Severin Almiri, William Encinas, Ruben Kaesmacher, Johannes Dobrocky, Tomas Schankin, Christoph J. Abegg, Mathias Piechowiak, Eike I. Raabe, Andreas Gralla, Jan Mordasini, Pasquale Clin Neuroradiol Original Article PURPOSE: We hypothesized that due to its specific characteristics, the Casper(TM) RX carotid stent (CP) might be particularly suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we compared it to the commonly used Precise Pro RX(TM) stent (PP). METHODS: A total of 15 patients with IIH (median age 28.7 years) were reviewed retrospectively. Technical aspects as well as peri- and postinterventional complication rates were examined in patients treated with CP (n = 10) and the PP (n = 5). Improvements in cerebrospinal fluid opening pressure (CSF OP), transstenotic pressure gradient (TSPG) and clinical symptoms were also assessed. RESULTS: Stent delivery was easier and more successful with the CP than the PP (difficult/failed stent delivery 0.0% versus 57.1%) and consequently achieved with less attempts (≥ 2: 0.0% versus 40.0%). No severe peri- or postinterventional complications or instances of in-stent thrombosis and/or stenosis were observed during follow-up. Improvement of CSF OP and TSPG immediately after VSS as well as at 6‑month follow-up was comparable between the CP and PP group. Both groups showed substantial and similar decreases in intensity and frequency of headache. Almost all patients with other IIH-related symptoms showed either improvement or complete resolution of those symptoms after VSS. All patients who were available for interview (n = 12/15) reported a substantial improvement in quality of life. CONCLUSION: VSS using the CP seems to be safe and effective. The CP may reduce the risk of difficult or failed stent delivery in patients with challenging intracranial venous anatomy. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01024-2) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2021-05-18 2021 /pmc/articles/PMC8463398/ /pubmed/34003319 http://dx.doi.org/10.1007/s00062-021-01024-2 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Belachew, Nebiyat F.
Baschung, Severin
Almiri, William
Encinas, Ruben
Kaesmacher, Johannes
Dobrocky, Tomas
Schankin, Christoph J.
Abegg, Mathias
Piechowiak, Eike I.
Raabe, Andreas
Gralla, Jan
Mordasini, Pasquale
Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
title Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
title_full Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
title_fullStr Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
title_full_unstemmed Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
title_short Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
title_sort casper versus precise stent for the treatment of patients with idiopathic intracranial hypertension
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463398/
https://www.ncbi.nlm.nih.gov/pubmed/34003319
http://dx.doi.org/10.1007/s00062-021-01024-2
work_keys_str_mv AT belachewnebiyatf casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT baschungseverin casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT almiriwilliam casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT encinasruben casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT kaesmacherjohannes casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT dobrockytomas casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT schankinchristophj casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT abeggmathias casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT piechowiakeikei casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT raabeandreas casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT grallajan casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension
AT mordasinipasquale casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension